Shares of ARS Pharmaceuticals, Inc. (SPRY) have gained 5.3% over the past four weeks to close the last trading session at $6.38, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25.33 indicates a potential upside of 297%. The average comprises three short-term price targets ranging from a low of $18.00 to a high of $30.00, with a standard deviation of $6.43. While the lowest est ...

公司股价与分析师目标价 - The RealReal (REAL) 股价在过去四周上涨3.6%，收于11.78美元，分析师平均目标价18美元，预示潜在上涨52.8% [1] - 八位分析师的目标价范围从最低15.00美元到最高20.00美元，标准差为2美元，最低目标价预示27.3%的上涨，最乐观目标价预示69.8%的上涨 [2] - 分析师目标价常因商业利益而被过度乐观设定，且实证研究表明其很少能准确指示股票实际价格走向 [7][8] - 低标准差代表分析师对股价方向与幅度有高度共识，可作为进一步研究潜在基本面驱动因素的起点 [9] 盈利预期与股价潜力 - 分析师对REAL盈利前景的乐观情绪增强，表现为盈利预测修正的强烈一致，这是股价上涨的合理理由 [11] - 过去30天，当前年度的Zacks共识盈利预测上调7.1%，有两项预测上调且无下调 [12] - REAL目前拥有Zacks排名第2位（买入），属于基于盈利预测因素排名的前20%股票，这更明确地指示了近期潜在上涨空间 [13]